Free Trial
ASX:BD1

BARD1 Life Sciences (BD1) Stock Price, News & Analysis

BARD1 Life Sciences logo

About BARD1 Life Sciences Stock (ASX:BD1)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
801,545 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

BARD1 Life Sciences Limited engages in the research, development, and commercialization of non-invasive diagnostic products for the early detection of cancer to enhance patient outcomes and save lives in Australia. Its cancer diagnostics portfolio includes commercialized hTERT test used as an adjunct to urine cytology testing; and diagnostic tests in development for ovarian, breast, lung, prostate, and pancreatic cancers. The company is also providing Molecular NET technology, including its EXO-NETTM product to capture and purify exosomes. BARD1 Life Sciences Limited was incorporated in 1983 and is headquartered in Notting Hill, Australia.

Receive BD1 Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BARD1 Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

BD1 Stock News Headlines

Life Kit
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

BD1 Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that BARD1 Life Sciences investors own include Vulcan Energy Resources (VUL), Splitit Payments (SPT), Meta Platforms (META), Lake Resources (LKE), Kalium Lakes (KLL) and Collins Foods (CKF).

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
Current Symbol
ASX:BD1
CIK
N/A
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.27 million
Price / Cash Flow
4.33
Book Value
A$0.36 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (ASX:BD1) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners